Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

Quick Read

• JPMorgan raised Lilly to $1,400 and RBC to $1,500, with both banks anchoring their bull cases almost entirely on GLP-1 drugs.

• Lilly’s Nvidia-partnered AI drug discovery platform, quietly funded by GLP-1 cash flows, represents a $1 trillion opportunity Wall Street has yet to price in.

• Few companies combine billions in current pharmaceutical revenue, decades of proprietary clinical data, and cutting-edge AI partnerships the way Lilly does.

• Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the cloud computing shift. 

Eli Lilly (NYSE:LLY) has already become the dominant name in metabolic medicine, but the market may still be valuing only the business it has today rather than the platform it is building for tomorrow.

Wall Street’s Lilly Targets Are All About GLP-1 Drugs

Wall Street continues to raise its expectations for Eli Lilly, but nearly every bullish argument revolves around its GLP-1 portfolio.

JPMorgan Chase recently raised its price target on Lilly to $1,400, pointing to continued growth from Mounjaro, Zepbound, orforglipron, and retatrutide, as well as international expansion. RBC Capital Markets went further, lifting its Lilly price target to $1,500 from $1,250 based largely on the company’s GLP-1 opportunity.

The argument makes sense. Lilly’s current growth engine is enormous.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

Retatrutide is particularly interesting because it goes beyond traditional GLP-1 medicines. The drug is a triple agonist that activates receptors for GLP-1, GIP, and glucagon. The goal is to combine appetite regulation with improved energy metabolism, potentially producing greater weight loss than existing treatments.

That is the story investors know. It is also the story already reflected in many Wall Street models.

24/7 Wall St.

Wall Street is obsessed with GLP-1, but the real breakthrough is a hidden AI-biology engine they’re completely overlooking.
© 24/7 Wall St.

Lilly’s AI Opportunity Is Flying Under The Radar

Artificial intelligence is what’s missing from that valuation conversation. Lilly is not just selling medicines; it is building a vertically integrated AI-powered biology platform.

The company has something many AI-focused drug discovery startups do not: massive proprietary clinical data generated from decades of research and millions of patient interactions. That data becomes increasingly valuable when paired with machine learning systems that can identify drug targets, predict outcomes, and accelerate development.

Lilly has also partnered with Nvidia (NASDAQ:NVDA) through its AI co-innovation lab to develop computational drug discovery capabilities. The company has worked with AI biotech firm Insilico Medicine as part of the broader effort to combine AI and biology.

AI is transforming drug discovery by helping companies analyze biological systems at a scale that was previously impossible. The irony is that Lilly’s GLP-1 success may actually provide the financial foundation for this AI buildout. The company is generating enormous cash flows from Mounjaro and Zepbound, giving it resources to invest in the next generation of medicine.

The Market Is Pricing Lilly’s Past — Not Its Future

Lilly already trades at a premium valuation because investors recognize the strength of its GLP-1 franchise. However, the market appears to be assigning little value to the AI-biology opportunity underneath it. That creates an unusual setup.

Many AI investments today are expensive because investors are paying for future potential without significant current revenue. Lilly offers the opposite profile: a profitable pharmaceutical company with billions in existing demand that is quietly adding an AI platform on top.

Granted, AI-driven drug discovery is still developing. Not every AI partnership will produce a blockbuster medicine, and pharmaceutical research remains filled with uncertainty. Drug failures are common, even for companies with deep resources.

That said, Lilly has a unique combination:

• A leading GLP-1 franchise generating current revenue

• Proprietary clinical data accumulated over decades

• Partnerships with leading AI technology companies

• A growing pipeline of next-generation medicines

Few companies sit at the intersection of healthcare, artificial intelligence, and large-scale commercialization the way Lilly does.

Key Takeaway

In short, investors buying Lilly solely for Mounjaro and Zepbound are focusing on the opportunity everyone already sees. The GLP-1 business alone may justify higher valuations, especially as international expansion and next-generation drugs develop. But the bigger opportunity may be the AI-powered drug discovery platform being built underneath the business.

Wall Street’s $1,400 to $1,500 price targets tell the GLP-1 story. The market has not yet fully priced in the AI-biology story. For long-term investors, that overlooked piece could become Lilly’s next major growth catalyst.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

Contact editorial@247wallst.com for any questions or corrections.